The Effect of Long-term Daily Stimulation of the Brain With Pulsed Electromagnetic Fields on Parkinsons Disease

The Effect of Long-term Treatment of Parkinson's Disease With T-PEMF

The goal of this clinical trial is to learn to what extent daily stimulation of the brain with transcranial pulsed electromagnetic fields (T-PEMF) works to treat persons with Parkinson's Disease. The main questions it aims to answer are:

• How does 6 months of daily treatment (30 minutes/day) with T-PEMF affects neuro-mechanical and molecular biological factors compared with placebo treatment in persons with Parkinson's disease?
• How does 12 months of daily treatment (30 minutes/day) with T-PEMF affects neuro-mechanical and molecular biological factors in persons with Parkinson's disease an does 12 months of T-PEMF alters the need for medication intake?

The neuro-mechanical outcomes are compared with the "natural" progression of the disease as well as with a healthy reference group. Furthermore, it will be examined whether 12 months of T-PEMF treatment alters the need for medication intake.

Participants in the intervention group will:

• receive one 30 min treatment session daily for 12 months
• receive either T-PEMF or sham treatment for the first 6 months
• receive active T-PEMF treatment the last 6 months
• visit for tests before treatment initiation, after 6 months of treatment and after 12 months of treatment.

Intervention Groups

Inclusion Criteria:

• Diagnosed with idiopathic Parkinson's disease
• The participant must be able to understand, accept, and complete the planned procedures
• Parkinson's symptoms in the medicated state must correspond to Hoehn & Yahr stage 1 or 2
• Mini Mental-State Examination score > 22

Exclusion Criteria:

• Cancer in the brain, neck, or head area
• Presence of active medical implants
• Epilepsy
• Alcoholism
• Substance abuse
• Open wound on the scalp
• Severe psychopathological disorders
• Pregnancy
• Changes in pharmacological anti-Parkinson medication within the last 6 weeks prior to the start of T-PEMF treatment
• Anticoagulant treatment with Marevan, Marcoumar, Pradaxa, Eliquis, Xarelto, Lixiana, Novostan, Fragmin, or Innohep
• Neurological disease other than Parkinson's disease
• Previous stroke
• Reduced motor function caused by conditions other than Parkinson's disease

Control Group with Parkinson's Disease

Inclusion Criteria:

• Diagnosed with idiopathic Parkinson's disease
• The patient must be able to understand, accept, and complete the planned procedures
• Parkinson's symptoms in the medicated state must correspond to Hoehn & Yahr stage 1 or 2
• Mini Mental-State Examination score > 22

Exclusion Criteria:

• Neurological disease other than Parkinson's disease
• Reduced motor function caused by conditions other than Parkinson's disease

Healthy Reference Group:

Inclusion Criteria:

-The patient must be able to understand, accept, and complete the planned procedures

Exclusion Criteria:

• Neurological disease
• Reduced motor function caused by condition